Accurate adiposity assessment is critical for understanding obesity-related disease risks, but current clinical measurement methods have significant limitations.
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA – Pharmaceutical Technology
The Danish companies aim to jointly develop a GLP-1RA administered once a month. Credit: Kittyfly / Shutterstock Novo Nordisk and Ascendis Pharma have agreed to